Study of Safety and Efficacy of Eltrombopag Maintainance Therapy in Patients After an Induction Treatment with Eltrombopag 50 mg Orally Once Daily.
Phase of Trial: Phase IV
Latest Information Update: 27 May 2015
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 27 May 2015 New trial record